In summary, we identified that SFE inactivated the NFκB pathway and down-regulated TNFAIP3 and PLAU expression to suppress ESCC cell proliferation and metastasis, providing new insights into the anticarcinogenic activity of SFE and confirming SFE as a potential chemotherapeutic agent. The gene discussed is TNFAIP3; the disease is esophageal squamous cell carcinoma.